(Q36196473)

12 August 2017

1 reference

title

The use of cannabinoids in multiple sclerosis (English)

1 reference

12 August 2017

0 references

Lara Teare

1

1 reference

12 August 2017

John Zajicek

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

published in

1 reference

12 August 2017

volume

14

1 reference

12 August 2017

issue

7

1 reference

12 August 2017

page(s)

859-869

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

12 August 2017

1 reference

Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Molecular characterization of a peripheral receptor for cannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Cannabinoid receptor localization in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Distribution of cannabinoid receptor messenger RNA in the human brain: an in situ hybridization histochemistry with oligonucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

The capsaicin receptor: a heat-activated ion channel in the pain pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Vanilloid receptors take a TRP beyond the sensory afferent☆

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Local inflammation increases vanilloid receptor 1 expression within distinct subgroups of DRG neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Peripheral capsaicin receptors increase in the inflamed rat hindpaw: a possible mechanism for peripheral sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Isolation and structure of a brain constituent that binds to the cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

The endocannabinoid system: a general view and latest additions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

2-Arachidonoylglycerol and the cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Cannabinoids control spasticity and tremor in a multiple sclerosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Effect of cannabinoids on spasticity and ataxia in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Tetrahydrocannabinol for tremor in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

The effect of cannabis on tremor in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Effects of delta-9-tetrahydrocannabinol on human immune function and host defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Cannabinoids and neuroinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Role of natural killer cells and TCR gamma delta T cells in acute autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammatory versus anti-inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Increased release of interleukin-12p40 in MS: association with intracerebral inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Reactive nitrogen intermediates in human neuropathology: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

The cannabinoid dexanabinol is an inhibitor of the nuclear factor-kappa B (NF-kappa B).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Cannabinoids: potential anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

The perceived effects of smoked cannabis on patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.859

10.1517/13543784.14.7.859

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference